About TNX-1700 TNX-1700, a fusion protein of TFF2 and albumin, is in preclinical development for the treatment of gastric and colorectal cancer in combination with PD-1 blockade. TNX-1700, in-licensed ...
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.
Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of ...
Details of Cresilon's presentation are as follows: ...
WALTHAM, Mass. and BOULDER, Colo., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
All Environmental Studies majors participate in public poster presentations as part of the thesis process. A poster session is organized for Wednesday in the last week of the fall and winter semesters ...
SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results